Uridine triacetate

Research use only, not for human use.

Uridine triacetate (RG 2133 triacetate) (Tri-O-acetyl uridine), an orally active prodrug of uridine, is efficiently absorbed in the gut and swiftly deacetylated in the circulation to release free uridine.

Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS).

Uridine triacetate inhibits [3H]uridine uptake in ENT1 and ENT2 overexpressed HeLa cells, with IC50s of 28.4 μM and 228.4 μM respectively.

Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced toxicity in 5-FU overdose mice.Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced 5-FU toxicityin DPD deficiency mice.Animal Model:5-FU overdose (i.p., 300 mg/kg) BALB/c mice model Dosage:2 g/kg Administration:Oral gavage, every 8 h for 15 total doses.Result:Improved the survival rate to 90%, 60%,30%, 20%, 0% and 0% in the groups initiated within 24, 48, 72, 96, 120 and 144 h, respectively.Animal Model:5-ethynyluracil-induced (i.p., 2mg/kg) DPD (dihydropyrimidine dehydrogenase) deficiency mice model Dosage:2 g/kg Administration:Oral gavage, every 8 h for 15 total doses.Result:Improved the survival rate to 100% when initiated 4 h after 5-FU, 80% when initiated within 24 h.Improved the survival rate to 40%, 50%,20%, 30% and 0% in groups initiated within 48, 72, 96, 120 and 144 h, respectively.

——

Others

Other Targets

Others

——

——

4105-38-8

370.31

C15H18N2O9

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (270.04 mM; )H2O : 10 mg/mL (27.00 mM; Ultrasonic)

CC(=O)OCC1OC(C(OC(C)=O)C1OC(C)=O)N1C=CC(=O)NC1=O

——

(-20℃)

With Ice Pack

≥ 2 years